Engineered Gut Bacteria for Oral Phenylalanine Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hyperphenylalaninemia, particularly phenylketonuria (PKU), are costly, difficult to adhere to, and often cause side effects, with a need for more effective and reliable long-term management of phenylalanine levels.
Innovation Solution
Genetically engineered non-pathogenic bacteria that express phenylalanine metabolizing enzymes (PME) such as phenylalanine ammonia lyase (PAL) and L-amino acid deaminase (LAAD) are introduced into the gut to reduce toxic phenylalanine levels, utilizing phenylalanine transporters for enhanced uptake.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If protein-restricted diet is used to treat PKU, then blood phenylalanine levels are controlled, but patient compliance becomes difficult and quality of life deteriorates
Solution Approach 1:
The patent introduces engineered bacteria as an intermediary agent that resides in the gut and actively metabolizes phenylalanine. These bacteria express phenylalanine ammonia lyase (PAL) and other enzymes to convert excess phenylalanine into non-toxic metabolites, thereby mediating the control of blood phenylalanine levels without requiring strict dietary restriction from the patient.
2Reliability
If cofactor therapy (tetrahydrobiopterin) is administered, then phenylalanine metabolism is improved, but treatment cost increases significantly
Solution Approach 1:
The patent employs engineered bacteria as a cost-effective alternative to expensive cofactor therapy. The bacteria are administered orally and persist in the gut, providing continuous phenylalanine metabolism. This approach replaces the need for costly lifelong cofactor supplementation while maintaining effective phenylalanine level control.
3Productivity
If oral PAL enzyme therapy is used, then phenylalanine degradation is enhanced, but enzyme availability at reasonable cost becomes limited
Solution Approach 1:
The patent merges the PAL enzyme function with a living bacterial host. Instead of administering isolated PAL enzyme, the bacteria are engineered to carry and express the PAL gene along with phenylalanine transporter genes. This combination allows the bacteria to actively take up phenylalanine and degrade it continuously, overcoming the limitations of enzyme availability and stability associated with oral enzyme therapy.
4Reliability
If PEG-PAL injectable treatment is administered, then phenylalanine levels are reduced, but injection site reactions and antibody formation occur
Solution Approach 1:
The patent replaces the mechanical injection method with an oral administration route. The engineered bacteria are administered orally and naturally colonize the gut, eliminating the need for injections. This substitution avoids injection site reactions and reduces the risk of immune responses associated with repeated parenteral administration of foreign proteins.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered bacteria effectively lower blood phenylalanine levels, providing a stable and long-term treatment option with reduced side effects and cost, improving the management of PKU symptoms.
Implementation Method 1
The engineered bacteria express phenylalanine metabolizing enzymes (PME) such as phenylalanine ammonia lyase (PAL) and L-amino acid deaminase (LAAD) to reduce toxic phenylalanine levels
Implementation Method 2
utilizing phenylalanine transporters for enhanced uptake
Data Source
AI summary
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.